CYCLERION THERAPEUTICS INC - COMMON STOCK (CYCN)

CUSIP: 23255M105

Q3 2023 13F Holders as of 30 Sep 2023

Type / Class
Equity / COMMON STOCK
Shares outstanding
4,330,313
Total 13F shares
552
Share change
0
Total reported value
$2,000
Price per share
$3.62
Number of holders
1

Quarterly Holders Quick Answers

What is CUSIP 23255M105?
CUSIP 23255M105 identifies CYCN - CYCLERION THERAPEUTICS INC - COMMON STOCK in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of CYCN - CYCLERION THERAPEUTICS INC - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Slate Path Capital LP
13F
Company
11%
357,880
$1,474,466 30 Jun 2023
13F
MFN Partners Management, LP
13F
Company
5%
169,460
$696,481 30 Jun 2023
13F
FMR LLC
13F
Company
4.9%
164,949
$677,941 30 Jun 2023
13F
Artal Group S.A.
13F
Company
mixed-class rows
138,955
mixed-class rows
$572,000 30 Jun 2023
13F
VANGUARD GROUP INC
13F
Company
2.4%
81,169
$334,416 30 Jun 2023
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.88%
29,722
$122,157 30 Jun 2023
13F
BlackRock Finance, Inc.
13F
Company
0.53%
18,000
$74,160 30 Jun 2023
13F
CAPTRUST FINANCIAL ADVISORS
13F
Company
0.43%
14,631
$60,280 30 Jun 2023
13F
JANE STREET GROUP, LLC
13F
Company
0.4%
13,364
$55,060 30 Jun 2023
13F
ACADIAN ASSET MANAGEMENT LLC
13F
Company
0.16%
5,437
$22,000 30 Jun 2023
13F
MORGAN STANLEY
13F
Company
0.02%
823
$3,391 30 Jun 2023
13F
ROYAL BANK OF CANADA
13F
Company
0.02%
839
$3,000 30 Jun 2023
13F
GROUP ONE TRADING LLC
13F
Company
0.02%
540
$2,219 30 Jun 2023
13F
UBS Group AG
13F
Company
0.01%
186
$766 30 Jun 2023
13F
RHUMBLINE ADVISERS
13F
Company
0%
22
$94 30 Jun 2023
13F
WELLS FARGO & COMPANY/MN
13F
Company
0%
14
$58 30 Jun 2023
13F
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
13F
Company
0%
1
$4 30 Jun 2023
13F
Andreas Busch
3/4/5
Chief Scientific Officer
class O/S missing
135,000
20 Jan 2022
Anjeza Gjino
3/4/5
Chief Financial Officer
class O/S missing
135,000
20 Jan 2022
Cheryl Gault
3/4/5
Chief Operating Officer
class O/S missing
135,000
20 Jan 2022
George H. Conrades
3/4/5
Director
class O/S missing
20,000
14 Jun 2022
Marsha Fanucci
3/4/5
Director
class O/S missing
20,000
14 Jun 2022
Michael Mendelsohn
3/4/5
Director
class O/S missing
20,000
14 Jun 2022
Ole Isacson
3/4/5
Director
class O/S missing
20,000
14 Jun 2022
Stephanie Lovell
3/4/5
Director
class O/S missing
20,000
14 Jun 2022
Kevin Churchwell
3/4/5
Director
class O/S missing
10,000
24 Jun 2021

Institutional Holders of CYCLERION THERAPEUTICS INC - COMMON STOCK (CYCN) as of Q3 2023

As of 30 Sep 2023, CYCLERION THERAPEUTICS INC - COMMON STOCK (CYCN) was held by 1 institutional shareholder that filed Form 13F with the SEC. Together, they reported ownership of 552 shares. The largest 1 holders included Artal Group S.A.. This page lists 1 institutional shareholders reporting positions in this security for the Q3 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q3 2023 vs Q2 2023 Across Filers

Q2 2023 holders
1
Q3 2023 holders
1
Holder diff
0
Investor Q2 2023 Shares Q3 2023 Shares Share Diff Share Chg % Q2 2023 Value $ Q3 2023 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .